期刊文献+

舒肝解郁胶囊联合奥氮平对精神分裂症患者抑郁症状的影响及安全性研究 被引量:1

Study on the effect and safety of Shugan Jieyu capsules combined with olanzapine tablets for depressive symptoms in patients with schizophrenia
收藏 分享 导出
摘要 目的 研究舒肝解郁胶囊联合奥氮平治疗精神分裂症的效果及安全性,分析其对患者抑郁症状的影响.方法 将80例精神分裂症患者按随机数字表法分为对照组和观察组,每组40例.对照组采用奥氮平进行治疗;观察组采用舒肝解郁胶囊与奥氮平进行联合治疗.治疗期间禁止服用其他抗抑郁药物、抗精神病药及心境稳定剂.结果 两组治疗后卡尔加里抑郁量表(CDSS)、阳性、阴性症状量表(PANSS),匹兹堡睡眠质量指数(PSQI),生活质量量表(SQLS)总评分与治疗前相比均有所改善,差异均有统计学意义(均P<0.05);且观察组治疗后CDSS评分为(3.4±2.5)分、PANSS评分为(36.2±7.5)分、PSQI评分为(3.4±2.5)分、SQLS总评分为(79.1±16.2)分,均优于对照组的(2.8±2.0)分、(40.5士8.7)分、(5.8±3.3)分、(59.4±19.1)分,差异均有统计学意义(t=5.942、2.368、3.666、4.975,均P<0.05).治疗后两组总胆固醇、三酰甘油、收缩压、舒张压、血糖均有所降低,与治疗前比较,差异均无统计学意义(t=1.265、0.425、1.224、1.236、0.670,均P>0.05),且两组组间差异均无统计学意义(均P>0.05).治疗后对照组有效率(67.5%)低于观察组(85.0%),差异有统计学意义(χ2 =4.267,P<0.05).两组各并发症发生率差异均无统计学意义(χ2 =0.139、0.164、0.105、0.263、0.263、0.180,均P>0.05).结论 采用奥氮平联合舒肝解郁胶囊治疗精神分裂症效果显著,安全性高,可改善患者抑郁症状,调节机体代谢水平,提高患者睡眠与生活质量. Objective To study the effect and safety of Shugan Jieyu capsules combined with olanzapine tablets in the treatment of schizophrenia,and to analyze its effects on the patients’ depressive symptoms.Methods According to the digital table,80 patients with schizophrenia were randomly divided into control group and observation group,40 cases in each group.The control group was treated with olanzapine,while the observation group was given olanzapine combined with Shugan Jieyu capsules.During the treatment,the other antidepressants,antipsychotics and mood stabilizers were prohibited.Results After treatment,the scores of CDSS,PANSS,PSQI and SQLS in the two groups were improved,and the differences were statistically significant(all P 〈 0.05).The CDSS score was (3.4 ± 2.5) points,PANSS score was (36.2 ± 7.5) points,PSQI score was (3.4 ± 2.5) points and SQLS total score was (79.1 ± 16.2)points in the observation group,which were all better than those in the control group[CDSS score was (2.8 ± 2.0) points,PANSS score was (40.5 ± 8.7) points,PSQI score was (5.8 ± 3.3) points and SQLS total score was (59.4 ± 19.1) points],the differences were statistically significant (t =5.942,2.368,3.666,4.975,all P 〈 0.05).After treatment,TCHO,TG,SBP,DBP and GLU were decreased in both two groups,but no significant differences were shown compared with before treatment(t =1.265,0.425,1.224,1.236,0.670,all P〉 0.05),and there were no significant differences between the two groups (all P 〉 0.05).After treatment,the total effective rate of the control group(67.5%) was lower than 85.0% of the observation group,the difference was statistically significant (χ2 =4.267,P 〈 0.05).There were no significant difference in the incidence of complications between the two groups(χ2 =0.139,0.164,0.105,0.263,0.263,0.180,all P 〉0.05).Conclusion For the treatment of schizophrenia,combined therapy of olanzapine tablets and Shugan Jieyu capsules has significant effect and higher saf
作者 王轶虎 崔力军 潘鑫 陶百平 Wang Yihu, Cui Lijun, Pan Xin, Tao Baiping (Department of Psychiatry, the Third People ~ Hospital of Huzhou , Huzhou , Zhejiang 313000, China ( Wang YIt , Pan X, Tao BP ) ;Department of Clinical Laboratory,the Third People's Hospital of Huzhou , Huzhou , Zhejiang 313000, China ( Cm LJ)
出处 《中国基层医药》 CAS 2017年第20期3053-3057,共5页 Chinese Journal of Primary Medicine and Pharmacy
基金 浙江省湖州市科技计划项目(2014GYB31)
关键词 精神分裂症 抑郁 舒肝解郁胶囊 奥氮平 Schizophrenia Depression Shugan Jieyu capsules Olanzapine
  • 相关文献

参考文献17

二级参考文献243

共引文献231

同被引文献6

引证文献1

投稿分析

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部 意见反馈